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ABSTRACT
Introduction Research on the benefits of ‘arts’
interventions to improve individuals’ physical, social
and psychological well-being is growing, but evidence
on implementation and scale-up into health and social
care systems is lacking. This protocol reports the
SHAPER-Implement programme (Scale-up of Health-Arts
Programmes Effectiveness-Implementation Research),
aimed at studying the impact, implementation and scale-
up of: Melodies for Mums (M4M), a singing intervention
for postnatal depression; and Dance for Parkinson’s (PD-
Ballet) a dance intervention for Parkinson’s disease. We
examine how they could be embedded in clinical pathways
to ensure their longer-term sustainability.
Methods and analysis A randomised two-arm
effectiveness-implementation hybrid type 2 trial design
will be used across M4M/PD-Ballet. We will assess the
implementation in both study arms (intervention vs
control), and the cost-effectiveness of implementation.
The design and measures, informed by literature and
previous research by the study team, were refined through
stakeholder engagement. Participants (400 in M4M;
160 in PD-Ballet) will be recruited to the intervention or
control group (2:1 ratio). Further implementation data
will be collected from stakeholders involved in referring
to, delivering or supporting M4M/PD-Ballet (N=25–30 for
each intervention).
A mixed-methods approach (surveys and semi-structured
interviews) will be employed. ‘Acceptability’ (measured
by the ‘Acceptability Intervention Measure’) is the
primary implementation endpoint for M4M/PD-Ballet.
Relationships between clinical and implementation
outcomes, implementation strategies (eg, training) and
outcomes will be explored using generalised linear mixed
models. Qualitative data will assess factors affecting the
acceptability, feasibility and appropriateness of M4M/
PD-Ballet, implementation strategies and longer-term
sustainability. Costs associated with implementation and
future scale-up will be estimated.

Strengths and limitations of this study
► Scale-up of Health-Arts Programmes Effectiveness-

Implementation Research-Implement is the largest
known study of its kind, comprising multidisciplinary implementation and evaluation teams, with
consistent stakeholder engagement embedded
throughout.
► The study allows large-scale psychometric validation of newly developed implementation measures.
► Provides an example of how large-
scale hybrid
studies can be conducted within community settings using a synergistic methodology with broad
applicability.
► Dance for Parkinson’s and Melodies for Mums will
be trialled in specific geographic areas in England,
further assessment of the interventions across
England will be required to assess the wider benefit.
Ethics and dissemination SHAPER-PND (the M4M trial)
and SHAPER-PD (the PD trial) are approved by the West
London and GTAC (20/PR/0813) and the HRA and Health
and Care Research Wales (REC Reference: 20/WA/0261)
Research Ethics Committees. Study findings will be
disseminated through scientific peer-reviewed journals
and scientific conferences.
Trial registration numbers Both trials are registered with
NIH US National Library of Medicine, ClinicalTrials.gov. The
trial registration numbers, URLs of registry records, and
dates of registration are: (1) PD-Ballet: URL: NCT04719468
(https://eur03.safelinks.protection.outlook.com/?url=
https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%
2Fshow%2FNCT04719468%3Fterm%3DNCT04719468%
26draw%3D2%26rank%3D1&data=04%7C01%7Crachel.
davis%40kcl.ac.uk%7C11a7c5142782437919f808d903
111449%7C8370cf1416f34c16b83c724071654356%
7C0%7C0%7C6375441942616) (date of registration: 22
Jan 2021). (2) Melodies for Mums: NCT04834622 (https://
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INTRODUCTION
The use of arts interventions (ie, ‘creative methods of
expression such as drama, music and visual arts’1) to
improve health and social care outcomes and reduce
service utilisation costs is an internationally growing area
of research.1–4 In 2017, the UK’s All-
Party Parliamentary Group on Arts, Health and Wellbeing published a
report on the benefits of arts interventions, alongside ten
stakeholder-led recommendations (from patients, health
and social care professionals, artists, academics, charities, policy-makers and parliamentarians) on facilitating
the implementation and scale-
up of ‘arts’ into health
and social care systems nationally.1 Two years on, the
WHO’s scoping review of the global academic literature
(2000–2019)2 identified over 900 publications, including
200 reviews, systematic reviews, meta-analyses and meta-
syntheses covering over 3000 studies, and 700 additional
studies. Taken the evidence collectively, arts interventions are an effective method to help treat a plethora of
physical, social and psychological problems across the
lifespan.1–4
Despite the promising evidence, progress on successfully embedding art interventions in health and social care
systems has been slow. Presently, many ‘arts’ are delivered
in small geographic or healthcare pockets, operating at
the fringe of the care sector rather than receiving mainstream funding.1 5 While lack of sustainable funding, weak
partnerships with commissioners and unclear referral
pathways partly account for this1 5 research is required to
establish cost-effective, scalable solutions so that the full
benefits to the wider population can be reached.
The current protocol reports the design and evaluation
of the ‘Scale-up of Health-Arts Programmes Effectiveness-
Implementation Research’ (SHAPER-
Implement)—
part of a larger programme (referred to as ‘SHAPER’6
aimed at investigating ways to implement and deliver arts
interventions at scale. We focus on two different health
conditions: postnatal depression (PND) and Parkinson’s disease (PD). These represent a significant fiscal
and public health burden and pose considerable affliction on the individuals affected (and, where applicable,
their carers).7–14 While pharmacological treatments can
be effective for controlling/alleviating symptoms,7 9 they
are fraught with challenges: for PND, it is poor uptake
and adherence,15–18 while for PD, it is overemphasis on
treating the motor symptoms at the expense of non-
motor functioning.19–21
Melodies for Mums (M4M) (for mums with PD) and
Dance for Parkinson’s (PD-Ballet) (for individuals with
PD) are two approaches to symptom management, that
have been piloted with promising results.22–30 Both have
already been implemented across certain locations in
London, UK, but are not being delivered at scale, thus
only reach a fraction of eligible individuals.
2

We plan to scale-
up M4M/PD-
Ballet and examine
how we can embed them into clinical pathways so that a
greater number of individuals can benefit. Our ambition
is to be as inclusive as possible, reaching out to individuals
who may not be undergoing treatment for their condition (as well as those that are), and ultimately for Clinical
Commissioning Groups (eg, the ‘payers’ in the National
Health Service, UK) to commission the interventions so
they can be delivered in a sustainable way beyond the end
of our research.
The entire SHAPER programme centres on tripartite
objectives. Due to the complexity of the study design, this
protocol reports the implementation effectiveness evaluation (ie, the SHAPER-Implement programme) of M4M/
PD-Ballet (objectives 2 and 3, described below). The clinical effectiveness evaluation (objective 1) is reported in
parallel protocols.31 32
Objective 1
To assess the clinical effectiveness of M4M/PD-
Ballet—
described in detail in the clinical protocols.31 32
Objective 2
To examine the implementation effectiveness of M4M/
PD-Ballet, including uptake, adoption, perceived acceptability, appropriateness, feasibility, fidelity, unintended
consequences and sustainability, and the impact of
established implementation strategies (eg, training in
the delivery of M4M/PD-
Ballet) on implementation
effectiveness.
Objective 3
To assess implementation costs and cost effectiveness, including
costs associated with implementing M4M/PD-Ballet into
existing care pathways, health service, partner organisations and commissioning, costs to service users attending
M4M/PD-Ballet vs the benefit in terms of quality-adjusted
years of life lived, and the impact of M4M/PD-Ballet when
delivered at scale, on the wider utilisation of healthcare
and other services.

METHODS AND ANALYSIS
Design
SHAPER-
Implement is a two-
arm effectiveness-
implementation hybrid type 233 trial of M4M/PD-Ballet.
Randomisation will be single-
blinded (assessments
performed by a blinded rater) and in a 2:1 ratio. M4M
participants will receive the singing programme (intervention) or be encouraged to attend non-music classes
in the community or online (control). PD-Ballet participants will receive a dance programme (dance-
based
training and a post-session Tea-and-Biscuit social time)
or follow the standard treatment per the local pathway
(control) and attend the post-training ‘Tea-and-Biscuit’
gatherings via an online platform.
Table 1 details how M4M/PD-Ballet meet the criteria
proposed by Curran et al33 for a hybrid type 2 trial.
Soukup T, et al. BMJ Open 2022;12:e055691. doi:10.1136/bmjopen-2021-055691
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Study characteristics for hybrid trial type 2, as per Curran et al
criteria33

Trialled arts interventions
Melodies for Mums

PD-Ballet

Research aims

Determine feasibility and potential utility
of an implementation intervention/
strategy
Determine effectiveness of a clinical
intervention*

Determine feasibility and potential
utility of M4M to facilitate future
implementation and scale up
Determine clinical effectiveness of
M4M

Determine feasibility and potential
utility of PD-Ballet to facilitate future
implementation and scale up
Determine clinical effectiveness of
PD-Ballet

Research questions

Does the implementation method show
promise (either alone or in comparison
with another method) in facilitating
implementation of a clinical treatment?
Will a clinical treatment work in these
settings/ for these patients?*

Will the implementation method
show promise (alone) in facilitating
M4M in people with PND?
What is the clinical impact of M4M?

Will the implementation method
show promise (alone) in facilitating
PD-Ballet in people with PD?
What is the clinical impact of PD-
Ballet?

Unit of randomisation

Provider, clinical unit, facility or system,
as per type although may be non-
randomised, for example, case study
Patient or clinical unit, as per type 1

Providers, as per type 3 (non-
randomised)
Patients, as per type 1 (randomised)

Providers, as per type 3 (non-
randomised)
Patients, as per type 1 (randomised)

Comparison conditions

Provider, clinical unit, facility, system:
Facility, as per hybrid type 3
implementation as usual, or competing
Treatment as usual, as per hybrid
implementation strategy although may be type 1
non-randomised, for example, case study
Placebo, treatment as usual, or competing
treatment, as per type 1

Facility, as per hybrid type 3
Treatment as usual, as per hybrid type
1

Sampling frames

Providers/clinics/facility/systems:
consider ‘optimal’ cases
Patient: limited restrictions, but some
inclusion/exclusion criteria

Providers/facility: artists,
psychiatrists/neurologists, referrers,
commissioners, support staff;
community centres
Patient: inclusion/exclusion criteria
used

Providers/facility: artists,
psychiatrists/neurologists, referrers,
commissioners, support staff; dance
centres
Patient: inclusion/exclusion criteria
used

Evaluation methods

Mixed method; quantitative, qualitative;
formative and summative
Quantitative, summative

Quantitative surveys (AIM,60 IAM,60
FIM,60 NoMaD,64 costing proforma)
and interviews62
Quantitative surveys (EPDS65; EQ-5D
3L63)

Quantitative surveys (AIM,60 IAM,60
FIM,60 NoMaD,64 costing proforma)
and interviews62
Quantitative surveys (†EPDS65; EQ-5D
3L63)

Measures

Adoption of clinical treatment and fidelity
to it, as well as related factors
Patient symptoms and functioning, possibly
cost effectiveness

Adoption of M4M, fidelity of its
delivery and receipt, acceptability,
appropriateness, feasibility,
sustainability, reach, unintended
consequences, contextual factors,
implementation strategies,
implementation costs
Patient symptoms and functioning,
cost effectiveness

Adoption of PD-Ballet, fidelity of its
delivery and receipt, acceptability,
appropriateness, feasibility,
sustainability, reach, unintended
consequences, contextual factors,
implementation strategies,
implementation costs
Patient symptoms and functioning,
cost effectiveness

Bold type: information relating to the implementation effectiveness evaluation. Normal type: information relating to the clinical effectiveness evaluation, discussed in
more detail in a separate protocols31 32
*Curran et al: ‘one of these aims/research questions might take precedence, for example in a case where the test of an implementation intervention/strategy is
exploratory’.33
AIM, Acceptability of Intervention Measure; EPDS, Edinburgh Postnatal Depression Scale; FIM, Feasibility of Intervention Measure; IAM, Intervention
Appropriateness Measure; M4M, Melodies for Mums; NMSS, Non-Motor Symptoms Scale; NoMaD, Implementation measure based on Normalization Process
Theory; PD-Ballet, Dance for Parkinson’s; PND, postnatal depression.

Contextual constraints meant it was not feasible to
randomise the implementation side of the trial (ie, allocate participants to different implementation strategies):
but we will examine the effectiveness of the implementation strategies used to deploy M4M/PD-Ballet.
Setting
SHAPER-
Implement is a multisite, multidisciplinary,
community-based study in London, UK. Funded by the
Wellcome Trust, it is a collaboration between the Centre
for Implementation Science, King’s College London;
King’s Health Partners; the Department for Behavioural
Science and Health and the Institute of Mental Health,
Soukup T, et al. BMJ Open 2022;12:e055691. doi:10.1136/bmjopen-2021-055691

University College London, and two award-winning arts
organisations: Breathe Arts Health Research and English
National Ballet (ENB). King’s holds a long-established
commitment to embedding arts, health and well-being in
education and research34 35 and was the research partner
for landmark publications in the area.1
Health conditions
PND is a serious and the most common perinatal mental
health condition, affecting 10%–20% of women in pregnancy and after birth.11 If left untreated the impact on
women and their families can be devastating11 36 37 with
symptoms including fatigue, anhedonia, insomnia and
3
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Interventions
Drawing from Curran et al’s ‘hybrid’ framework33 (see
table 1) through an intensive 4-
month stakeholder
engagement with artists, researchers, clinicians and
commissioners, we considered five elements critical to
assessing the relevance of the interventions:
► Suitability: M4M/PD-Ballet address a need within the
health sector—there are growing patient populations with the conditions and lack of effective current
service provision.
► Quality and face validity: M4M/PD-
Ballet are ‘high-
quality’ interventions with carefully designed and
tailored activities, developed in partnership between
centres of academic excellence and renowned arts
organisations.
► Inclusivity: M4M/PD-
Ballet are ‘all-
inclusive’. They
have good uptake, not only with those already engaged
in the arts. They also appear to ‘reach-out’ to individuals that are disengaged in other forms of treatment
for PND/PD (eg, pharmacological approaches).
► Effectiveness: there is evidence to show M4M/PD-Ballet
improves symptoms and quality of life and can
achieve better adherence than pharmacological
approaches.23–26 28–30
► Scalability: M4M/PD-
Ballet are not overly complex,
thus have the potential to be scaled-up, embedded
in clinical pathways and commissioned by the health
sector.6
M4M6 31 is delivered in partnership with Breathe Arts
Health Research (https://breatheahr.org/melodies-for-
mums/). A breathe-trained artist (the workshop leader)
and support assistant deliver ten weekly singing sessions to
a group of mums with PND and their babies. Classes start
with welcome songs, followed by music activities, ranging
from short vocal exercises and simple lullabies to longer
4

songs that attendees learn gradually over the weeks.
Songs can be relaxing, with mothers encouraged to hug/
stroke their babies as they sing, or energetic, with mothers
standing and moving with their babies. Instruments (eg,
guitars and ukuleles) are used by the workshop leader,
accompanied by simpler instruments for mothers/babies
to use. Mothers are encouraged to write their own songs,
developing lyrics together relating to their babies or
experiences of motherhood.6 31 Recordings of the singing
sessions are made available to attendees at the end.
M4M has been subject to a three-
arm randomised
controlled trial (RCT) of 134 mothers and a preliminary
process evaluation. Significantly faster improvements
in symptoms for mothers with moderate-
severe PND
(measured by the Edinburgh Postnatal Depression Scale
(EPDS)), than mothers in usual care24 were observed.
Levels of depression consistently declined—by week 6,
65% of mothers no longer had an EPDS ≥13 (ie, indicating no more than mild depression); increasing to 73%
by week 10.24 Increase in the frequency of mothers singing
to their babies outside the classes, perceived mother–
infant closeness and a greater decrease in cortisol levels
when compared with social play were also reported.23–25
The process evaluation showed that M4M reached the
correct target demographic, was delivered with a high
level of fidelity and programme satisfaction was high—
88% of mothers agreed the classes were well tailored, and
100% would recommend M4M to another mother.26 29 30
Several challenges, however, were highlighted by mothers,
workshop leaders and the project coordinator (eg, timing
sessions with babies’ routines)—while this did not hinder
the continuation of M4M, it nonetheless suggests that
implementation of M4M could be improved.26
PD-Ballet6 32 is based on the ENB’s pre-existing ‘Dance
for Parkinson’ (DfP) programme (referred to as
PD-Ballet for the SHAPER research) and delivered in
partnership with the ENB (https://www.ballet.org.uk/
project/dance-for-parkinsons/). Led by an ENB trained
DfP Associate Artist and Associate Musician who deliver
12 weekly sessions to individuals with PD (carers/relatives
can also attend), sessions comprise live music, dance and
vocal exercises. Each session comprises 75 min of activity,
followed by social time and refreshments (up to 1 hour)
so that participants can get to know fellow attendees and
form social networks. Content, inspired by the ENB’s
classical and contemporary works, provides a framework
for participants to explore narrative, themes, concepts
and music to promote freedom of expression. A performance sequence is developed at the end of PD-Ballet,
combining all elements of the programme. Dance material is adapted to be inclusive (catering for differing
levels of mobility) so that everyone can participate fully.
For PD-
Ballet content will be further developed for
the three distinct stages of motor advancement (mild/
moderate/severe)—something which has not been done
before within the existing DfP programme. Prior to the
programme, individuals attend an introductory session
with their assigned group and are given the opportunity
Soukup T, et al. BMJ Open 2022;12:e055691. doi:10.1136/bmjopen-2021-055691
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irritability and thoughts of suicide.7 8 37 38 Therapy (eg,
cognitive-
behavioural therapy) or medication can be
prescribed to help treat PND but progress can be slow,
may involve long wait times for treatment (for therapy) or
prolonged use of medication38–40—thus other options for
symptom management need to be explored.
PD is one of the world’s fastest growing chronic neurodegenerative disorders, with those aged over 70 being
particularly vulnerable.14 41 42 It affects over 145 000
people in the UK alone42 with prevalence rates expected
to rise by around 18% between 2018 and 2025 (to over
168 000), and doubling by 2065.10 42 Symptoms relate to
motor (eg, tremor, bradykinesia, freezing of gait) and
non-
motor (eg, sleep disturbance, drooling, cognitive
decline)9 10 functioning. Currently, there is no cure for
PD—and the disease has a progressive course.9 10 Pharmacological treatments can alleviate symptoms and improve
quality of life but are largely aimed at addressing motor
functioning, leaving the non-
motor symptoms often
unrecognised or under-
treated.10 43 44 Alternative non-
pharmacotherapies are necessary to slow down disease
progression.10 43 44

Open access

Programme structure and delivery

Melodies for Mums

PD-Ballet

Arts partner
Targeted health condition

Breathe Arts Health Research
Postnatal depression

English National Ballet
Parkinson’s disease

Setting

Community children’s centres OR online
(depending on COVID-19 guidelines)

Community dance studios OR online
(depending on COVID-19 guidelines)

Delivery structure

A weekly 1-hour group session over 10 weeks

A weekly 2 hours 15 min 12-group
session over 12 weeks

N of intervention cycles

10 cycles, with a morning and afternoon cycle
held across 5 separate10 weekly periods

3 cycles (stratified by motor
advancement—mild/moderate/
severe)

N of participants per cohort

12–15

30–35

Total N of participants in the
intervention

270 mums (plus their respective babies)

107 individuals with Parkinson’s*

Follow-ups (as related to the delivery
of sessions)

No follow-up

No follow-up

Artists per session

2 (1 artist, 1 assistant)

Total N of participants in the control

N=130 mums

4 (2 associate dance artists/2
associate musicians), plus 1 artist-in-
training
N=53

All those involved in M4M and PD-Ballet will receive training in a standardised format beforehand the delivery of the programmes.
*The three cohorts differ in the severity of Parkinson’s symptoms: mild, moderate and severe
†The 2 days training is required for each stage of motor advancement so the trainer would need to attend three 2 day training sessions if they
running programmes for all three groups of motor advancement (mild/moderate/severe).
N, number; PD-Ballet, Dance for Parkinson’s.

to attend a ballet performance and a behind the scenes
event.6 32
Initial testing of PD-Ballet in London, and its regional
affiliated hub partners, has proven to be replicable,
resulting in it being trialled and established in four other
locations in the UK (Oxford, Cardiff, Ipswich and Liverpool). An independent evaluation led by the University
of Roehampton (on scaling-
up the programme, experiences and benefits of participation across 4 years and
the effects on the body, daily activities and social participation) reported high levels of perceived value from
an emotional, social and artistic perspective.28 Additionally, PD-Ballet can decrease social isolation and improve
quality of life,22 with participants highly motivated and
viewing PD-Ballet as an important part of their lives.27
Equally, while recent systematic reviews and studies on the
effects of performing acts modalities (including dance
and ballet) reported promising benefits on Parkinson’s
symptoms45 46 very few RCTs have investigated the benefits of ‘dance’ in both motor and non-motor symptoms,
pointing to the need for this research.
SHAPER-Implement will build on previous research—
conducting a full RCT (for PD-Ballet), a follow-up RCT
scaled to a larger number of mothers (for M4M), and a
process evaluation and examination of the implementation and potential cost-effectiveness of delivery at scale
(for both) (see table 2 for further details on M4M/
PD-Ballet).
Soukup T, et al. BMJ Open 2022;12:e055691. doi:10.1136/bmjopen-2021-055691

Implementation and adaption: COVID-19 pandemic
As a result of the first national lockdown in the UK on
23 March 2020 and the guidelines that followed, M4M/
PD-Ballet were adapted to be delivered online and preliminary research into the feasibility of using an online platform is underway. While the plan moving forward (ie,
when the trials begin) will be to deliver PD-Ballet and
M4M face-face, this will be continually reviewed based on
the government guidelines on COVID-19 at the time, and
the switch to remote delivery of the programmes will be
made if necessary.
Theoretical underpinning
The Medical Research Council’s (MRC) framework for
evaluating complex interventions47 48 informed the study
design for intervention development, implementation
and evaluation processes.
The ‘Implementation Science Research Development’
tool,49 allowed us to operationalise the MRC guidance
into the overall design of SHAPER-
Implement, along
with the research team’s knowledge and experience of
conducting hybrid trials.50 We also tailored intervention
delivery using the COM-B model51 by considering factors
that could affect individuals’ capability, opportunity and
motivation to engage with M4M/PD-Ballet.
The Consolidated Framework for Implementation
Research (CFIR)52 53 will be used to assess factors affecting
the implementation M4M/PD-Ballet. The ‘Expert Recommendations for Implementing Change’ (ERIC) project’s
5
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Participants
For M4M, 400 mothers (with their babies) will be
randomised 2:1 to the intervention (N=270) versus control
(N=130). Mothers over 18 years of age with symptoms of
PND (defined as a diagnosis of major depressive disorder
according to the Structured Clinical Interview for DSM-IV
Disorders and a score of ≥10 on the EPDS) and a baby 0–9
months old, will be eligible. Mothers with an EPDS score
of <10 will be excluded and signposted to other support
services within the community (eg, mother–baby groups)
but invited to re-screen for future cycles of the intervention (in case their symptoms change).
For PD-Ballet, 160 individuals will be recruited: 2:1 to
the intervention (N=107) versus control (N=53). Participants will be 18 years old or over with a diagnosis of idiopathic PD according to the UK PD Brain Bank criteria
and Hoehn Yarhr stages I–V. Individuals with a diagnosis
of other Parkinsonism or an indication of dementia
through a score of ≤21 on the Montreal Cognitive Assessment will be excluded.
Ballet) will also be
Individuals (for both M4M/PD-
excluded if they are unable to: understand English; give
informed consent; access and attend the singing/dance
sessions online (due to COVID-19) through an internet-
connected device (eg, mobile phone, computer), or face-
to-face (government guidelines permitting).
Individuals who decline participation or withdraw from
M4M/PD-Ballet will be asked (providing they are willing)
to provide their reason(s), so that barriers to uptake
(from ‘decliners’) or continued participation (from
‘withdrawers’) can be identified and addressed.
SHAPER-
Implement will also collect data on stakeBallet
holders’ attitudes and experiences of M4M/PD-
(N=25–30, respectively) so that challenges relating to
intervention delivery can be reviewed and overcome.
A description of power and sample size calculations for
M4M/PD-Ballet can be found in the corresponding clinical protocols.31 32
Patient and public involvement
We are engaging with members of the public and patients
throughout SHAPER-
Implement and at every stage of
the research process. We have formed advisory groups
comprising individuals who have already completed the
PD-Ballet and M4M programme. To date, these individuals have provided feedback on (but not limited to) our
6

study design, data collection measures, recruitment strategies and methods for disseminating findings.
Wider stakeholder engagement
In addition to patients/the public, engagement with
other stakeholders is also critical to the success and scalability of M4M/PD-Ballet. We will hold regular meetings
with: ‘deliverers’—artists/staff involved in delivering
Ballet; ‘referrers’—those who refer individM4M/PD-
Ballet (eg, general practitioners or
uals to M4M/PD-
neurologists (PD-Ballet); psychiatrists, health visitors and
midwives (M4M) and; ‘supporters’—additional staff who
support the running of M4M/PD-Ballet. To date, examples of involvement include contributing to the overall
study design; critically reviewing methods of assessment
for relevance and clarity; and exploring and facilitating
referral pathways for recruitment.
Developing theory of change
We will conduct stakeholder workshops to develop theory
of change (ToC) and logic models. The ToC element
will focus on summarising M4M/PD-Ballet at a strategic
level, capturing possible pathways for the change process
to achieve our outcomes. The logic models will focus on
the programme specifics, assessing the change process
at the level of implementing M4M/PD-
Ballet. We will
advance the traditional logic model by drawing from
the recently developed implementation research logic
model.58 We will examine inputs (eg, time), activities (eg,
recruitment), outputs (eg, publications), outcomes (eg,
symptoms), implementation determinants (identified in
the CFIR52 53), implementation strategies, (drawing from
the ERIC project54 55) and mechanisms of action resulting
from the implementation outcomes (informed by the
implementation outcome taxonomy59 and RE-AIM).56 57
Recruitment
Recruitment for M4M will be through: (1) signposting via
health and social care professionals, including midwives
and health visitors; (2) healthcare referrals, including
general practitioners, clinical psychologists, psychiatrists
and self-referral; (3) weighing clinics and other community and clinical centres for postnatal mothers, and; (4)
social media groups and online forums aimed at new
mothers (eg, of the consent form, refer to online supplemental file 1)
Recruitment for PD-
Ballet will be through: (1) the
Movement Disorders Outpatient Clinic at King’s College
Hospital; (2) London South Parkinson’s Excellence
Network (PEN) using the London South PEN patient
section of the website; (3) London South and National
Clinical Research Network websites and the EUROPAR
website https://parkinsons-london.co.uk/europar/; (4)
the Study Hub website (Parkinson’s UK) and; (5) the
ENB.
Stakeholders will be recruited through Breathe’s (for
M4M) and ENB’s (for PD-Ballet) network of artists, staff
and others involved in M4M/PD-Ballet.
Soukup T, et al. BMJ Open 2022;12:e055691. doi:10.1136/bmjopen-2021-055691
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compendium of implementation strategies54 55 will guide
the identification of implementation strategies that could
overcome some of the factors affecting implementation.
The Reach Effectiveness Adoption Implementation
Maintenance (RE-AIM) framework,56 57 which comprises
domains on ‘implementation’ and ‘effectiveness’ and
is suited to address challenges of blended effectiveness-
implementation designs, guided the selection of implementation measures alongside Proctor et al43 taxonomy of
implementation outcomes.

Open access

Measures
Measures will be standardised across M4M/PD-
Ballet,
piloted and further refined (where applicable) through
a codesign process with stakeholders to ensure their
suitability.
Data on the acceptability60 of M4M/PD-Ballet (primary
implementation outcome measure) and training in the
delivery of M4M/PD-Ballet (SHAPER-Implement’s established implementation strategy), and data on the feasibility60 and appropriateness60 will be collected at three
timepoints.
Implementation costs will be assessed using a previously developed costing proforma61 62 on the time and
financial resource associated with implementing M4M/
PD-
Ballet within existing care pathways. To explore
commissioning costs, feedback from provider organisations will be sought (those responsible for providing the
interventions) to establish a range of plausible unit prices
that the National Health Service (NHS)/partner organisations would be required to pay. To establish the impact
of M4M/PD-Ballet on the wider utilisation of services (ie,
other health and service costs), service utilisation questionnaires on the frequency of contact with other NHS/
non-NHS services over a 3-month retrospective period will
be completed. Reported service use will be costed using
published unit cost estimates for healthcare and other
services. The EQ5D 3L63 will be used to evaluate quality
of life outcomes and quality-adjusted life year outcomes
in the short-term.
To explore sustainment of M4M/PD-
Ballet, the
‘Normalisation Measure Development’ questionnaire64
will be administered postintervention.
Enrolment onto M4M/PD-Ballet will assess uptake and
participation data and attrition rates will be used to assess
adherence.
Sociodemographic data on participants and stakeholders will be collected (see table 3 for further details
on measures).
Qualitative measures
Semi-structured interviews partly informed by the study
team’s methods of assessment for previous hybrid trials50 62
will complement the quantitative findings. Interviews will
occur post-intervention and examine:
► Implementation strategies used to deliver M4M/
PD-
Ballet alongside strategies that may be important to consider by the local centres wishing to
Soukup T, et al. BMJ Open 2022;12:e055691. doi:10.1136/bmjopen-2021-055691

►
►

►

►

►
►

Ballet after completion of
implement M4M/PD-
SHAPER-Implement.
Factors affecting the perceived acceptability, appropriateness and feasibility of M4M/PD-Ballet.
Fidelity of delivery—whether M4M/PD-Ballet is delivered in accordance with protocol (eg, number and
length of sessions, format and content covered).
Fidelity of receipt—how the content of M4M/
PD-Ballet is received by participants, including their
experiences of engagement, comprehension of the
content delivered, and application of acquired knowledge and skills to daily life.
Factors affecting the sustained use of the knowledge
and skills acquired from M4M/PD-Ballet for the long-
term management of PND/PD (from participants)
and the implementation of M4M/PD-Ballet into local
services after the completion of SHAPER-Implement
(from stakeholders).
Unintended consequences (positive and negative) of
M4M/PD-Ballet
Stakeholders’ willingness for continued involvement
in M4M/PD-Ballet (ie, intention to adopt) and participants’ intentions to use the knowledge and skills
gained from M4M/PD-Ballet and recommend M4M/
PD-Ballet to others.

Data analysis
Quantitative implementation outcomes
Parametric and non-p arametric tests will be employed
to compare survey responses between the two arms
of the trial for M4M/PD-B allet and the established
implementation strategy (ie, training arts leads/
artists). Linear, logistic and Poisson regression models
(depending on the distribution of the outcome) will
explore the relationship between implementation
(Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM)60 and clinical
trial primary (EPDS65 for M4M and MDS-M NS 66 for
PD-B allet) and secondary outcome. Potential moderators (eg, age of the age of the baby for M4M) of
the effect of implementation (AIM, IAM and FIM)
on clinical trial primary (EPDS65 for M4M and MDS-
MNS66 for PD-B allet) and secondary outcome will be
explored with the inclusion of an interaction term.
Mediation analysis using structural equation models
under the causal framework will be employed to
understand the potential pathways in which implementation outcomes and the implementation strategy
of ‘training’, impact on the effectiveness of M4M/
PD-B allet.67 68 All analyses will be conducted in STATA
V.16.0.
Psychometric assessment of the reliability, validity and factorial
structure of the implementation survey scales
The implementation outcomes scales are relatively
new, hence require psychometric assessment. Cronbach’s coefficient alpha will evaluate the reliability
7
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The start and end dates for the trials are September
2021–December 2023 (for M4M) and February 2022–
December 2022 (for PD-Ballet). Follow-up data will be
collected at 36 weeks so the full data collection for the
trials will end in May 2024 (for M4M) and May 2023 (for
PD-Ballet). It should be noted that more than one cycle
of each programme will run for each trial, and that these
cycles may overlap (ie, occur simultaneously) to varying
degrees for M4M/PD-Ballet—hence, the slightly different
durations of each of the trials.

Open access

Outcome

Definition

Form of measurement Timepoint(s)

Stakeholder group

Implementation effectiveness
Acceptability

Extent to which M4M/PD-Ballet are
AIM survey
perceived to be agreeable and acceptable for Interview
management of PND and PD, respectively.
Extent to which training in the delivery of
M4M/PD-Ballet (ie, SHAPER-Implement’s
established implementation strategy) is
considered acceptable to arts leads/artists.

During intervention,
Participants and wider
postintervention and 3–6 stakeholder groups
months postintervention
follow-up

Appropriateness

Extent to which M4M/PD-Ballet are perceived IAM survey
to be fit and relevant for management of PND Interview
and PD, respectively.

During intervention,
Participants and wider
postintervention and 3–6 stakeholder groups
months postintervention
follow-up

Feasibility

Extent to which M4M/PD-Ballet can be
successfully used or carried out to help
manage and improve PND and PD-related
effects.

FIM survey
Interview

During intervention,
Participants and wider
postintervention and 3–6 stakeholder groups
months postintervention
follow-up

Fidelity of delivery

Extent to which M4M/PD-Ballet sessions
were delivered according to protocol.

Interview

Postintervention

Deliverers

Fidelity of receipt

Extent to which M4M/PD-Ballet are received
as intended.

Interview

Postintervention

Participants

Adoption

Intention to adopt and use the knowledge
and skills learnt in M4M/PD-Ballet in
everyday management of PND and PD.

Interview

Postintervention

Participants and wider
stakeholder groups

Sustainability

Facilitators and barriers to sustained use of
M4M/PD-Ballet.

Interview and the
NoMad survey

Postintervention and
follow-up

Participants and wider
stakeholder groups

Uptake

The proportion and representativeness of
Trial records
individuals willing to participate in M4M/PD-
Ballet.

Baseline

Provided by trial
manager

Adherence

The number of individuals attending each
M4M/PD-Ballet session and the number of
dropouts

Throughout intervention Provided by trial
period
manager

Unintended
consequences

Interview
Positive or negative consequences that are
not anticipated at the time of implementation
of M4M/PD-Ballet.

Postintervention

Participants and wider
stakeholder groups

Implementation
strategies*

Strategies used to deliver and implement
M4M/PD-Ballet.

Interview

Postintervention

Wider stakeholder
groups

Costing proforma

Postintervention

Participants and wider
stakeholder groups

During and
postintervention

Participants

Trial records

Implementation costs and cost effectiveness
Implementation
costs

Costs associated with prospective
implementation of M4M/PD-Ballet.

Cost-benefit
analysis

Costs associated with M4M/PD-Ballet vs the EQ-5D 3L
benefits in terms of the outcomes.

Clinical effectiveness†
The impact of M4M/PD-Ballet on the clinical
outcomes of interest.

EPDS survey
NMSS survey

Baseline,
Participants
postintervention and 3–6
months postintervention
follow-up

*As part of SHAPER-Implement we will be assessing the acceptability and benefit of ‘training arts leads/artists’ in the delivery of M4M/PD-Ballet
(ie, our established implementation strategy) but we will also be examining other implementation strategies that may be of use in the wider-scale
implementation of M4M/PD-Ballet.
†For further information on the clinical effectiveness evaluations, please refer to the corresponding clinical protocols for M4M31 and PD-Ballet.32
AIM, Acceptability of Intervention Measure; EPDS, Edinburgh Postnatal Depression Scale (Melodies for Mums); FIM, Feasibility of Intervention
Measure; IAM, Intervention Appropriateness Measure; M4M, Melodies for Mums; NMSS, Non-Motor Symptoms Scale (Dance for Parkinson’s);
NoMAD, Implementation measure based on Normalization Process Theory; PD, Parkinson’s disease; PD-Ballet, Dance for Parkinson’s; PND,
postnatal depression; SHAPER, Scale-up of Health-Arts Programmes Effectiveness-Implementation Research.

(internal consistency) of the IAM, FIM and AIM scale-
items (values range from 0 to 1 with internal consistency deemed acceptable when Cronbach’s alpha 69 is
8

≥0.70 70). A confirmatory factor analysis model will be
fitted, using the weighted least square estimator with
a mean-a nd-v ariance-a djusted χ2 method to handle
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Table 3 Data collection plan for the implementation effectiveness evaluation of Melodies for Mums and PD-Ballet
interventions
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Health economic outcomes
Using a combination of empirical and modelling
methods, we will bring together evidence on clinical
endpoints, quality-o f-life, implementation and intervention costs, and epidemiological data on prevalence
and service utilisation to gauge the cost-e ffectiveness
of delivering M4M/PD-Ballet at scale. We will build
in evidence-b ased assumptions regarding the longer-
term health and service resource impacts beyond
the observable trial period. The cost-e ffectiveness of
scalability under differing scenarios will be assessed
with reference to existing thresholds, inclusive of
those currently used by the National Institute for
Health and Care Excellence for assessing programme
cost-
effectiveness. Uncertainty in estimates will be
explored through probabilistic and one-way sensitivity
analysis. Cost-effectiveness will be evaluated from an
NHS perspective, with a focus on exploring the incidence of incremental resource impacts associated
with utilisation of NHS funded resources.
Qualitative implementation outcomes
A systematic classification process of coding themes/
patterns in the data will be used with the main themes
predetermined deductively by the Proctor et al59
implementation outcomes framework and RE-
AIM.77
Subthemes will be shaped inductively with the data until
saturation is achieved. CFIR78 79 will be used to analyse
barriers/facilitators (anticipated and actual) to the implementation and sustainment of M4M/PD-
Ballet. NVivo
V.12 will be used for data analysis.
ETHICS AND DISSEMINATION
M4M and PD-Ballet have been reviewed and approved
by the West London and GTAC Research Ethics
Committee (Reference: 20/PR/0813) and the HRA
and Health and Care Research Wales Research Ethics
Committee (Reference: 20/WA/0261). Informed
consent will be sought from all research participants.
The results will be disseminated in academic journals
and conferences as well as other channels (including
to patients and the public in the centres and healthcare settings where the programmes are being delivered and through social media).
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ordered categorical items.71 To evaluate overall model
fit, the comparative fit index (CFI),72 the Tucker Lewis
index 73 and the root mean square error of approximation (RMSEA)74 will be calculated. A CFI and TLI value
of >0.90 indicates adequate fit to the data.75 A value of
RMSEA <0.05 indicates close fit, values between 0.05
and 0.08 suggest adequate model fit, and values >0.10
suggest poor model fit.75 Psychometric analysis will be
conducted using STATA V.16 and Mplus V.7.4.76
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CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES
Please complete this form after you have read the Information Sheet and/or listened to
an explanation about the research.
Title of Study:
SHAPER-PND: Community singing interventions for postnatal
depression: a hybrid type II effectiveness-implementation trial
Thank you for considering taking part in this research. One of the researchers from the research
team will explain the project to you before you agree to take part. If you have any questions
arising from the Information Sheet or explanation already given to you, please ask the
researcher before you decide whether you should join in. You will be given a copy of this
Consent Form to keep and refer to
at any time.
Your information may be subject to review by responsible individuals from the research team for
screening, monitoring and audit purposes.
Confidentiality will be maintained and you will not be identified in any research outputs.
Yes

No

I confirm that I understand that by ticking/initialling a ‘Yes’ box, I am consenting to being
involved in this element of the study. I confirm that I understand that by ticking/initialling
a ‘No’ box, I DO NOT consent to being involved in this element of the study.
1.
I confirm that I have read and understood the information sheet dated [30-Jul-2021,
version 2.1] for the above study. I have had the opportunity to consider the information and
asked questions which have been answered to my satisfaction.
2.
I consent voluntarily for myself and for my baby to be a participant in this study and
understand that I can withdraw from the study at any time, without having to give a reason.
3.
I consent to the processing of my personal information for the purposes explained to
me in the Information Sheet. I understand that such information will be handled confidentially, in
accordance with the terms of the General Data Protection Regulation.
4.
I agree that the research team may use my data for future research within and outside
the EU and understand that any such use of identifiable data would be reviewed and approved
by a research ethics committee. In such cases, as with this project, data will not be identifiable
in any report.
5.
I agree to be contacted in the future by King’s College London researchers who would
like to invite me to participate in follow up studies to this project, or in future studies of a similar
nature.
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6.
I agree to provide details of my GP and understand that if any safeguarding issues
arise, my GP might be contacted to discuss the best way to support me and my baby.
7.
I agree to record short videos being taken of play interaction in a comfortable setting
between my baby and me. This recording aims to look at how me and my baby interact with
each other and the information obtained can be used for our research.
8.
I agree to my views being shared in focus groups and subsequent interviews to be
recorded (in audio and/or video format) for data collection. The researchers may use a
transcription service to transcribe the recordings into a different format. I understand that my
identity will stay anonymous and I will not be identifiable in the published data or materials.
(optional)
9.
I agree to provide biological samples (saliva) throughout the study in accordance to the
study protocol. (optional)
10.
I agree to provide biological samples (hair) throughout the study in accordance to the
study protocol. (optional)
11.
My biological samples may be used for future studies and my data will remain
anonymous. (optional)
12.
I agree to provide biological samples (saliva only) of my baby in accordance to the
study protocol. (optional)
13.
The biological samples of my baby may be used for future studies and the data will
remain anonymous. (optional)
14.
I agree to be contacted by implementation science researchers to provide my views on
the study. I understand that my views may be video and audio recorded and published but I will
not be identifiable in any of the research outputs. (optional)
15.
I do not wish to participate in the study, but I agree to be contacted by implementation
science researchers for a brief interview, to explain why. (optional)
Note that you must consent to points 1-7 in order to be eligible for the study. Points 8-14 are not
mandatory but are still an integral part of the study. If you do not wish to participate in the study but
consent to being contacted to tell us why (optional), just tick point 15.

Participant:
________
Your Name

Date

Signature

Date

Signature

Researcher:
__________
Name of Researcher
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